Primo Lara, MD, on RCC: Expert Perspective on Three Key Papers
2017 ASCO Annual Meeting
Primo Lara, MD, of the University of California, Davis Comprehensive Cancer Center, discusses three top abstracts on treating advanced renal cell carcinoma with epacadostat, pembrolizumab, atezolizumab, bevacizumab, sunitinib, or pazopanib. (Abstracts 4505, 4507, 4515)
Lee S. Schwartzberg, MD, of West Cancer Center, reports on this past year’s progress of the ACCC initiative to speed adoption of immunotherapeutics in community practices.
Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)
Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.
Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, and pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. (Abstract LBA500)